Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cambridge Antibody Technology Group -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (402)	9/22/2003 11:04:10 AM
From: keokalani'nui	Read Replies (1) \| Respond to of 625

IMO, the most dyax could have received was nice, but nearly immaterial to CAT. Whatever was done to unwind the first deal proabably is not material either. BTW, I'm pretty sure the licensor ABT feels heat to pay out of CAT's share is serono. GENZ are tough, lawyerly s-o-b-s. May CAT have been very well advised. But the key news....the tgfb P1/2 trial is over. Data later 4q. And the coincidence, a fresh investment in CAT, and today CAT now commits funding to the tgfb JV. CAT just better not ever get behind on its genz-jv payments. All in all great news! Probably.